Match!
Amy L. Phillips
Merck Serono
Intensive care medicinePhysical therapyDiseaseMultiple sclerosisMedicine
70Publications
11H-index
344Citations
What is this?
Publications 69
Newest
#1Jacqueline Nicholas (OhioHealth)H-Index: 3
#2Natalie C. EdwardsH-Index: 3
Last. Amy L. Phillips (Merck Serono)H-Index: 11
view all 6 authors...
BACKGROUND Nonadherence to disease-modifying drugs (DMDs) for multiple sclerosis (MS) is associated with poorer clinical outcomes, including higher rates of relapse and disease progression, and higher medical resource use. A systematic review and quantification of adherence and persistence with oral DMDs would help clarify the extent of nonadherence and nonpersistence in patients with MS to help prescribers make informed treatment plans and optimize patient care. The objectives were to: 1) condu...
Source
#1Jacqueline Nicholas (OhioHealth)H-Index: 3
#2Natalie C. EdwardsH-Index: 3
Last. Amy L. Phillips (Merck Serono)H-Index: 11
view all 5 authors...
Source
Source
#1James D. BowenH-Index: 58
#2Chris M. KozmaH-Index: 19
Last. Amy L. Phillips (Merck Serono)H-Index: 11
view all 4 authors...
BackgroundAdministrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings.ObjectiveTo evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide).MethodsPatients from an administrative claims database (1 Jan 2012–31 Dec 2015) were selected if they: were 18–63...
1 CitationsSource
#1Maria K. Houtchens (Brigham and Women's Hospital)H-Index: 18
#2Natalie C. Edwards (Brigham and Women's Hospital)H-Index: 3
Last. Amy L. Phillips (Brigham and Women's Hospital)H-Index: 11
view all 5 authors...
Objective To compare pregnancy prevalence and complications in women with and without multiple sclerosis (MS). Methods This retrospective US administrative claims study used data from January 1, 2006, to June 30, 2015. All data for women with MS were included. A nationally representative 5% random sample from approximately 58 million women without MS was used to compute the dataset. Annual pregnancy rates, identified via diagnosis/procedure codes and adjusted for covariates, were estimated via l...
11 CitationsSource
#1Maria K. HoutchensH-Index: 18
#2Natalie C. EdwardsH-Index: 3
Last. Amy L. PhillipsH-Index: 11
view all 3 authors...
Objective To evaluate relapse rates and disease-modifying drug (DMD) treatment in US women with multiple sclerosis (MS) and a live birth. Methods This retrospective administrative claims database study used US commercial health plan data from women with MS and a live birth from January 1, 2006, to June 30, 2015. Relapses and DMD treatment were evaluated 1-year prepregnancy, during pregnancy, during puerperium (6 weeks postpregnancy), and 1-year postpregnancy. Relapse was defined as MS-related ho...
16 CitationsSource
Source
#1Natalie C. EdwardsH-Index: 3
#2Michael MunsellH-Index: 6
Last. Amy L. Phillips (Merck Serono)H-Index: 11
view all 4 authors...
AbstractObjective: To examine the time to first disease-modifying drug (DMD) treatment and to identify factors associated with early DMD initiation in newly-diagnosed patients with MS.Methods: This...
Source
#1Amy Perrin-Ross (LUC: Loyola University Chicago)
#2Chris M. KozmaH-Index: 19
Last. Amy L. Phillips (Merck Serono)H-Index: 11
view all 4 authors...
Objective: To evaluate the propensity for being highly adherent to subcutaneous interferon beta-1a (scIFNβ1a) versus dimethyl fumarate in patients with multiple sclerosis (MS). Background: Adherence to prescribed disease-modifying drug (DMD) treatment regimens is important for the optimization of patient care in MS. Design/Methods: Data from patients with MS were obtained from the US National Health and Wellness Survey or Lightspeed Research panel and its affiliates (eligible patients completed ...
1234567